SVB Wealth LLC Sells 25,191 Shares of Pfizer Inc. $PFE

SVB Wealth LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 17.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,047 shares of the biopharmaceutical company’s stock after selling 25,191 shares during the quarter. SVB Wealth LLC’s holdings in Pfizer were worth $2,939,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Horizon Financial Services LLC raised its stake in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. YANKCOM Partnership acquired a new position in Pfizer during the fourth quarter worth $28,000. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer during the third quarter worth $29,000. Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter worth $32,000. Finally, Torren Management LLC acquired a new position in Pfizer during the fourth quarter worth $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank initiated a Buy view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank
• Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus.
• Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer’s 6.5% Dividend Yield Looked Too Good to Be True — but Management Just Silenced the Skeptics
• Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors
• Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.
• Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Pfizer Stock Performance

Shares of PFE opened at $25.65 on Monday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $146.17 billion, a price-to-earnings ratio of 19.58 and a beta of 0.35. The stock has a 50 day moving average of $27.14 and a 200 day moving average of $26.16. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Royal Bank Of Canada reissued an “underperform” rating and issued a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. CICC Research started coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.74.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.